“…In another research, Inflammatory cytokines in tear and serum has checked 4 times within 6 months follow-up after plasma spots on Rats conjunctiva, and this study also reported no persistent inflammatory responses [29]. After 3 animal studies, human ocular surface diseases have been targeted to treating with atmospheric low-temperature plasma and published case series studies, including conjunctivochalasis, conjunctival cyst, pinguecula, pterygium, punctal occlusion, conjunctival concretion, pseudophakic bullous keratopathy, conjunctival nevus [15,[30][31][32][33][34]. All these novel modalities have been taught to ophthalmologists all over the world, as a safe, office-based and effective approaches [35].…”